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Abstract
A variety of foods have been implicated in symptoms of patients with Irritable Bowel Syndrome (IBS) but wheat products
are most frequently cited by patients as a trigger. Our aim was to investigate the effects of breads, which were fermented
for different lengths of time, on the colonic microbiota using in vitro batch culture experiments. A set of in vitro anaerobic
culture systems were run over a period of 24 h using faeces from 3 different IBS donors (Rome Criteria–mainly constipated)
and 3 healthy donors. Changes in gut microbiota during a time course were identified by fluorescence in situ hybridisation
(FISH), whilst the small -molecular weight metabolomic profile was determined by NMR analysis. Gas production was
separately investigated in non pH-controlled, 36 h batch culture experiments. Numbers of bifidobacteria were higher in
healthy subjects compared to IBS donors. In addition, the healthy donors showed a significant increase in bifidobacteria (P,
0.005) after 8 h of fermentation of a bread produced using a sourdough process (type C) compared to breads produced
with commercial yeasted dough (type B) and no time fermentation (Chorleywood Breadmaking process) (type A). A
significant decrease of d-Proteobacteria and most Gemmatimonadetes species was observed after 24 h fermentation of type
C bread in both IBS and healthy donors. In general, IBS donors showed higher rates of gas production compared to healthy
donors. Rates of gas production for type A and conventional long fermentation (type B) breads were almost identical in IBS
and healthy donors. Sourdough bread produced significantly lower cumulative gas after 15 h fermentation as compared to
type A and B breads in IBS donors but not in the healthy controls. In conclusion, breads fermented by the traditional long
fermentation and sourdough are less likely to lead to IBS symptoms compared to bread made using the Chorleywood
Breadmaking Process.
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Introduction
Irritable bowel syndrome (IBS) is a common functional
gastrointestinal disorder defined by the coexistence of abdominal
discomfort or pain associated with alterations in bowel habits [1].
Several studies have indicated that the aetiology of IBS is most
likely multi-factorial, due to abnormalities in intestinal motility,
visceral hypersensitivity, altered brain-gut interaction, food intol-
erance, abnormal gut microbiota and persistence of low-grade
inflammatory conditions [2]. Due to effects on modulating the
immune function, motility, secretion and gut sensation, probiotics
have been suggested to have the potential to exert a beneficial role
in managing IBS symptoms [3]. Furthermore, it has been
suggested that IBS patients could be characterized by a potential
dysregulation in energy homeostasis and liver function, which may
be improved through probiotic supplementation [4]. A recent
review of clinical trials using lactic acid bacteria (LAB) in patients
with IBS [5] showed improvement in abdominal pain, discomfort,
abdominal bloating and distension as main endpoints. Dietary
factors are also important in IBS as they are considered major
drivers for changes in the compositional and functional relation-
ship between microbiota and the host [6]. In fact, dietary
components are substrates for metabolism by the intestinal
microbial ecosystem, particularly influencing the growth and
metabolic activities of dynamic bacterial populations thriving in
the human colon. Studies on the relationships between diet and
symptoms in IBS suggest that elimination of potential culprit foods
can be helpful [7,8]. A variety of foods are thought to contribute to
IBS, but wheat is the dietary ingredient frequently cited by patients
as a trigger, with the exclusion of bread and other wheat products
often leading to partial or complete resolution of symptoms [7,9].
In particular, changes in the type of bread generally available to
consumers and the overall wheat content of the average diet may
be significant underlying reasons why problems of gas-related
gastrointestinal problems have increased. However, few studies
have examined the impact of different types of bread on
gastrointestinal symptoms in IBS and this is a topic worthy of
further consideration [9]. To date, there is evidence that a diet low
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in fermentable carbohydrates, particularly fermentable oligosac-
charides, disaccharides, monosaccharides and polyols (FODMAPs;
also referred to as fermentable short-chain carbohydrate) reduces
some symptoms associated with IBS [10–11]. In particular, Gibson
and Shepherd suggest that fermentable short-chain carbohydrates
can be a ‘problem high food source’ for those susceptible to IBS
when consumed in large amounts (no specific number suggested)
[10]. A recent study found that significantly more patients with
IBS who followed a low-FODMAP diet (76%) reported satisfac-
tion with their symptom response (decrease in symptoms)
compared with patients following a standard diet recommended
by the National Institute for Health and Clinical Excellence (54%)
[11]. Although interesting, it is not possible to say which particular
FODMAPs or sources of these are associated with gastrointestinal
symptoms. Therefore, based on these studies, no conclusions about
the impact of bread (or specific types of bread) on gastrointestinal
symptoms in IBS sufferers can be drawn, although, this would
seem to be a topic worthy of consideration.
A component of bread that has been suggested to help relieve
IBS symptoms by shortening transit time (mainly in those suffering
from constipation) is dietary fibre. However, two systematic
reviews found no effect of cereal bran on IBS symptoms [12–13].
In fact, insoluble fibre, the main fibre component of bran, may
increase symptoms in some IBS sufferers among whom reducing
intakes of insoluble fibre may reduce symptoms. Therefore, eating
white rather than whole meal bread may actually help relieve
symptoms [14–15]. More specifically, a change in the process of
wheat fermentation from the traditional long fermentation process
to the shorter, incomplete fermentation of the Chorleywood
Breadmaking Process (CBP) may have contributed to intolerance
to bread through effects on gut microbiota and fermentation.
Furthermore, another component of the CBP that has been
suggested to be related to gastrointestinal symptoms is an increased
percentage of yeast used in the fermentation process. However,
whereas no evidence supporting the role of yeasts in the
production of symptoms has been reported from clinical trials,
dietary elimination of yeasts and anti-fungal therapy have been
shown to be beneficial in IBS subjects [16]. Therefore, it is not
possible to confirm or reject claims that the higher amount of yeast
added to dough of bread made with CBP may be responsible for
gastrointestinal problems.
Recently, there has been a growing interest in investigating the
role of an altered gut microbiota in the pathogenesis of IBS [17–
22]. ‘‘Healthy’’ gut microbiota have either direct bactericidal
effects or can prevent the adherence of pathogenic bacteria to the
wall of the gastrointestinal tract [23]. Dysbiosis in the gut may
facilitate the adhesion of enteric pathogens in the human gut,
which can be associated with IBS symptoms [23]. Alteration in the
composition of the healthy microbiota and disturbed colonic
fermentation in IBS patients may play an important role in
development of IBS symptoms. Intestinal inflammation is gener-
ally believed to be associated with a reduced bacterial diversity
and, in particular, a lower abundance of, and a reduced
complexity in, the Bacteroidetes and Firmicutes phyla with a
specific reduction of abundance in the Clostridium coccoides
groups [24]. It has also been indicated that while Firmicutes are
reduced there is an increase in gammaproteobacteria in patients
with IBS [25]. In contrast to the general microbial dysbiosis
theory, some researchers have suggested the involvement of
specific taxa [26]. There have been a number of studies that have
also highlighted a lower abundance of F. prausnitzii [26].
In the present study, we investigated the impact of breads
fermented for different lengths of time on the human intestinal
microbiota, using in vitro batch culture experiments with faecal
donors from IBS patients and healthy control subjects. The main
bacterial groups of the faecal microbiota were determined using
16S rRNA-based analyses. Metabolic effects of the breads on the
microbial physiology were also studied using high resolution
1NMR-based metabolic profiling. Finally, the in vitro gas
production was determined in non-pH-controlled, 36 h faecal
static batch cultures. As such, the intention was to assess the
influence of bread making process on gut microbial fermentation
in vitro.
Materials and Methods
Preparation of three selected breads
Grain of wheat (cv Maris Widgeon) was milled commercially to
an extraction rate of 85% and was kindly supplied by Mr Andrew
Whitley and Bread Matters Limited (Macbiehill Farmhouse,
Lamancha, West Linton, Peeblesshire EH46 7AZ). Three types
of bread, A) conventional yeasted dough, zero bulk fermentation
time; B) conventional yeasted 16-hour sponge-and-dough and C)
30% sourdough, 4-hour refreshment stage, 5-hour final proof were
produced. Type A was prepared accordingly to the Chorleywood
Breadmaking Process (CBP). Types B and C include the
metabolism of endogenous flour components (yeasts, LAB,
enzymes, micro- and macro-nutrients) that are present in greater
quantity in flours containing more of the germ and bran layers.
All different type of breads (A, B and C) were prepared in the
Food Processing Centre (FPC) of the Department of Food and
Nutritional Sciences at the University of Reading (UK).
Simulated human digestion of bread (from mouth to
small intestine)
Frozen bread samples were thawed and 60 g of each sample
was processed by an in vitro simulation of upper gut digestion and
freeze dried as described by Maccaferri et al. [27]. Dialyses with
membrane of 100–200 Daltons cut off (Spectra/por 100–200 Da
MWCO dialysis membrane, Spectrum Laboratories Inc., UK)
were used to remove monosaccharides from the pre-digested
breads.
Compositional analyses of the dough and breadflour
samples by 1H NMR
NMR sample preparation was carried out according to a
modification of the procedures described [28–29]. Extraction into
80:20 D2O:CD3OD (1 mL) containing 0.05% w/v d4-TSP (1 mL)
was performed for three technical replicates, of 30 mg, for each
biological sample. 1H NMR data were collected as described
below.
After analysis, to minimize variation due to differing sample pH,
samples were evaporated and reconstituted in sodium phosphate
buffer in D2O (750 mL, pH=6, 300 mM) and data collection
repeated. 1H–NMR spectra were acquired under automation at
300uK on an Avance Spectrometer (Bruker Biospin, Coventry,
UK) operating at 600.0528 MHz and equipped with a 5 mm
selective inverse probe. Spectra were collected using a water
suppression pulse sequence with a relaxation delay of 5 s. Each
spectrum was acquired using 128 scans of 64 k data points with a
spectral width of 7309.99 Hz. Spectra were automatically Fourier
transformed using an exponential window with a line broadening
value of 0.5 Hz. Phasing and baseline correction were carried out
within the instrument software (Topspin v.2.1 and Amix (Analysis
of MIXtures software, v.3.9.11), Bruker Biospin). 1H chemical
shifts were referenced to d4-TSP at d0.00. Quantification of
individual metabolites was achieved using Chenomx Profiler
(Chenomx Inc., Alberta) software against an in-house reference
Breadmaking Process and Gut Microbiota
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library of metabolite signatures of authentic compounds, with
known concentrations, ran under identical conditions.
Collection and stool sample preparation
Faecal samples were obtained from 3 healthy human volunteers
(two males, one female; age 30 to 38 years; BMI: 18.5–25) who
were free of known metabolic and gastrointestinal diseases (e.g.
diabetes, ulcerative colitis, Crohn’s disease, irritable bowel
syndrome, peptic ulcers and cancer). All healthy faecal donors
had the experimental procedure explained to them and were given
the opportunity to ask questions. All donors then provided verbal
informed consent for the use of their faeces in the study and a
standard questionnaire to collect information regarding the health
status, drugs use, clinical anamnesis, and lifestyle was administrat-
ed before the donor was ask to provide a faecal sample. The
University of Reading research Ethics Committee exempted this
study from review because no donors were involved in any
intervention and waived the need for written consent due to the
fact the samples received were not collected by means of
intervention. For the IBS donors (Rome criteria - mainly
constipated), written informed consent was obtained in each case
and the study was approved by the St. Thomas’ Hospital Research
Ethics Committee (Ref 06/Q0702/74 - A study of mucosal and
luminal bacteria microbiota in irritable bowel syndrome). All
faecal samples collected from healthy and IBS donors were
collected on site, kept in an anaerobic cabinet (10% H2, 10% CO2
and 80% N2) and used within a maximum of 15 minutes after
collection. Samples were diluted 1/10 w/v in anaerobic PBS
(0.1 mol/L phosphate buffer solution, pH 7.4) and homogenised
(Stomacher 400, Seward, West Sussex, UK) for 2 minutes at 460
paddle-beats.
In vitro fermentations
Sterile stirred batch culture fermentation systems (50 ml
working volume) were set up and aseptically filled, with 45 ml
sterile, pre-reduced, basal medium [peptone water 2 g/L (Oxoid),
yeast extract 2 g/L (Oxoid, Basingstoke, UK), NaCl 0.1 g/L,
K2HPO4 0.04 g/L KH2PO4 0.04 g/L, MgSO4.7H2O 0.01 g/L,
CaCl2.6H2O 0.01 g/L, NaHCO3 2 g/L, Tween 80 2 mL (BDH,
Poole, UK), haemin 0.05 g/L, vitamin K1 10 mL, cysteine.HCl
0.5 g/L, bile salts 0.5 g/L, pH 7.0)] and gassed overnight with
oxygen free nitrogen (15 mL/min). The different pre-digested
breads, 5 g (1/10 w/v) were added to the respective fermentation
vessels just prior to the addition of the faecal slurry. The
temperature was kept at 37uC and pH was controlled between
6.7 and 6.9 using an automated pH controller (Fermac 260,
Electrolab, Tewkesbury, UK). Each vessel was inoculated with
5 ml of fresh faecal slurry (1/10 w/w) for both healthy and IBS
donors. The batch cultures (n = 3) were ran over a period of 24 h
and 5 mL samples were obtained from each vessel at 0, 4, 8 and
24 h for fluorescence in situ hybridisation (FISH) and 1H NMR
analysis.
In vitro enumeration of bacteria population by FISH
Numbers of predominant intestinal bacterial groups, as well as
total bacterial populations, were evaluated in samples from
in vitro batch culture system by fluorescence in situ hybridization
(FISH) analysis, as previously described by Martin-Pelaez and
colleagues [30]. The probes used are reported in Table 1. They
were commercially synthesised and 59-labelled with the fluorescent
Cy3 dye (Sigma, UK).
Short chain fatty acid analysis
Analysis was performed using ion exclusion high performance
liquid chromatography (HPLC) system (LaChrom Merck Hitachi,
Poole, Dorset UK) equipped with pump (L-7100), RI detector (L-
7490) and autosampler (L-7200). Samples (1 mL) from each
fermentation time point (1 mL) were centrifuged at 13,0006g for
10 min to remove bacterial cells and any particulate material.
Supernatants were filtered through a 0.22 mm filter unit (Millipore,
Cork, Ireland) and 20 mL injected into the HPLC, operating at a
flow rate of 0.5 mL/min with heated column at 84.2uC.SCFAs
(acetate, propionate, butyrate) and lactate were determined by
HPLC on an Aminex HPX-87H column (30067.8 mm, Bio-Rad,
Watford, Herts, UK). Degassed 5 mM H2SO4 was used as eluent
at a flow rate of 0.6 ml/min and an operating temperature of
50uC. Organic acids were detected by UV at a wavelength of
220 nm, and calibrated against standards of corresponding
organic acids at concentrations of 12.5, 25, 50, 75 and 100 mM.
Internal standard of 20 mM 2-ethylbutyric acid was included in
the samples and external standards.
1H NMR Metabolomic profile of supernatants from
fermentation
The fermentation supernatant from all time points was freeze-
dried, dissolved in 600 mL of phosphate buffer 0.2 M (pH 7.4) in
D2O plus 0.001% TSP and 550 mL transferred into 5 mm NMR
tubes for analysis. All NMR spectra were acquired on a Bruker
Avance DRX 700 MHz NMR Spectrometer (Bruker Biopsin,
Rheinstetten, Germany) operating at 700.19 MHz and equipped
with a CryoProbe from the same manufacturer [28–29]. They
were acquired using a standard 1-dimensional (1D) pulse sequence
[recycle delay (RD)-90u-t1-90u-tm-90u-acquire free induction
decay (FID)] with water suppression applied during RD of 2 s, a
mixing time (tm) of 100 ms and a 90u pulse set at 7.70 ms. For each
spectrum, a total of 128 scans were accumulated into 64 k data
points with a spectral width of 14005 Hz. A range of 2D NMR
spectra were performed on the same equipment for selective
samples, including correlation spectroscopy (COSY), total corre-
lation spectroscopy (TOCSY) and heteronuclear single quantum
coherence (HSQC) NMR spectroscopy. The FIDs were multiplied
by an exponential function corresponding to 0.3 Hz line
broadening. All spectra were manually phased, baseline corrected
and calibrated to the chemical shift of TSP (d 0.00). Metabolites
were assigned using our in house standard database, data from
literature [37–38] and confirmed by 2D NMR experiments.
Gas production rate determinations
Sterile glass tubes (186150 mm, Bellco, Vineland, New Jersey,
USA) containing 13.5 mL pre-reduced basal medium [peptone
water 2 g/L (Oxoid), yeast extract 2 g/L (Oxoid, Basingstoke,
UK), NaCl 0.1 g/L, K2HPO4 0.04 g/L, MgSO4.7H2O 0.01 g/L,
CaCl2.6H2O 0.01 g/L, NaHCO3 2 g/L, Tween 80 2 mL (BDH,
Poole, UK), haemin 0.05 g/L, vitamin K1 10 mL, cysteine-HCl
0.5 g/L, bile salts 0.5 g/L, pH 7.0)] were placed into the
anaerobic cabinet and kept overnight. Pre-digested breads (1%
w/v) were added to the fermentation tubes just prior to addition of
the faecal inocula (1/10 w/v) [39]. The tubes were then sealed
with a gas impermeable butyl rubber septum (Bellco, Vineland,
New Jersey, USA) and aluminium crimp (Sigma Aldrich,
Gillingham, Dorset, UK). Gas production was evaluated by
recording the headspace pressure (pounds per square inch; psi)
from each vial. Gas production experiments were performed in
four replicates for each type of bread. Vials were incubated at
37uC and continuously shaken. Pressure readings were obtained
Breadmaking Process and Gut Microbiota
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every 3 h up to 36 h fermentation period by piercing the rubber
caps with a U200/66 needle adaptor connected to a pressure
transducer (type 2200BGF150WD3DA; Keller Ltd, Dorchester,
Dorset, UK) with a T443A digital panel meter (Bailey and Makey
Ltd, Birmingham, UK). Pressure readings (psi) were converted
into gas volume (mL) using an established linear regression of
pressure recorded in the same vials with known air volumes at the
incubation temperature.
Statistical analysis
Differences between bacterial counts and SCFA profiles at 0, 4,
8 and 24 h fermentation for each substrate were tested for
significance using paired t-tests assuming equal variances and
considering a two-tailed distribution. To determine whether there
were any significant differences in the effect of the substrates;
differences at each time point were tested using 2-way ANOVA
with Bonferroni post-test. All analyses were performed using
GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, USA).
Metabolic profiles of fermentation supernatant were imported
into Matlab version R2010b (Mathworks UK) and statistical
algorithms were provided by Korrigan Sciences (Korrigan
Sciences Ltd, UK). To minimise variability due to water pre-
saturation, the water resonance region (d 4.70–5.05) was removed.
Data were then normalised to the probabilistic quotient as
previously described [40]. All statistical models were performed
using unit variance scaling. Principal component analyses (PCA)
were performed on all spectra in order to detect any outliers and to
identify patterns associated with volunteers, time, fermentation
condition or donor group. In order to optimise statistical
separation between samples derived from IBS and control donors
at 24 h, a partial least square discriminant analysis was also
performed using one predictive component. This later model was
validated using 1000 random permutations, and a p value was
calculated by rank determination of the model actual Q2Y value
(representing the goodness of prediction) among the Q2Y values
calculated for the permutated models. Finally, in order to focus on
the ethanol production in control- and IBS-derived samples, the
area under the ethanol triplet at 1.18 ppm was integrated and an
ANOVA followed by a multiple comparison test (TukeyHSD)
were performed in R (version 2.15).
Results
Compositions and properties of flour, doughs and breads
A sample of wheat cv Maris Widgeon was milled to 85%
extraction rate to give a flour fraction enriched in fibre and other
components derived from the bran and germ, compared to pure
white flour which is derived solely from the starchy endosperm.
This flour was similar to those used by many artisan bakers in the
UK. Three types of bread were produced, with yeast but zero bulk
fermentation (similar to the Chorleywood Breadmaking Process
(CBP) (which is used widely for factory production of bread in the
UK and many other countries) (type A), with yeast and 16 hours
fermentation (type B) and a sourdough process using a ‘‘starter
dough’’ and a total of 9 hours fermentation (type C). The
composition of major soluble polar metabolites in the flour,
doughs and bread samples were determined by 1H–NMR
(Table 2). Typically, flour contained lower amounts of the
abundant free sugars (maltose, glucose and fructose) that tended
to be broken down in the dough samples by a longer fermentation
process. Less abundant flour carbohydrates included sucrose and
raffinose. Sucrose levels were markedly lower in the CBP dough
and bread (type A) and in the dough and bread undergoing longer
fermentation (type B) but remained stable in the sourdough
samples. Sugars such as arabinose, xylose and galactose were not
detected in the flour spectra but were present in all the bread and
dough spectra. Increasing the fermentation time did not change
the amounts of these carbohydrates (CBP vs dough/bread B).
However, significantly higher levels of these sugars were released
by the sourdough process. In addition, the dough and bread
samples produced using the sourdough process contained higher
levels of glycerol and mannitol, the latter not being present in
bread B or that produced using the CBP. Organic acids showed
striking differences between the samples. As expected, lactate levels
were increased with longer fermentation and were very high in
both the sourdough (405 mmoles/g) and the sourdough bread
(111.4 405 mmoles/g). Other organic acid levels such as citrate
and malate also discriminated the samples. While the malate levels
fell to around 30% in the long fermentation samples compared
with the CBP process, the citrate levels remained stable even with
a longer fermentation process but were completely absent from the
sourdough product spectra, Succinate generally showed an
opposite profile, increasing during longer fermentation (B) but
Table 1. Oligonucleotide probes used in this study for FISH analysis.
Probe Target group Reference
EUB3381 Most bacteria [15]
EUB338II1 Most bacteria [15]
EUB338III1 Most bacteria [16]
Bac303 Bacteroides spp. [17]
Bif164 Bifidobacterium spp. [17]
Lab158 Lactobacillus-Enterococcus spp. [18]
Erec482 Most of the Clostridium
coccoides-Eubacterium rectale group
(Clostridium cluster XIVa and XIVb)
[19]
Chis150 Clostridium histolyticum group [19]
Prop853 Clostridium cluster IX [20]
Delta496a-b-c Deltaproteobacteria-Gemmatimonadetes group [21]
1These probes are used together in equimolar concentrations.
doi:10.1371/journal.pone.0111225.t001
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decreasing in the sourdough products. Interestingly, dough B was
the only sample containing low levels of acetic acid. In general, the
sourdough dough and resultant bread had significantly higher
contents of many polar metabolites than the CBP and long
fermentation doughs and breads. The majority of amino acid
(alanine, valine, leucine, isoleucine, glutamate, glutamine, aspar-
tate, phenylalanine, tryptophan, tyrosine and gamma-amino
butyric acid (GABA, a non-protein amino acid) were present in
higher concentrations in the sourdough samples and in some cases
also the bread made using this process. Similarly, signals
corresponding to methionine, whose levels were not detected in
other flour, bread or dough samples, were clearly present in the
spectra from the sourdough samples. Notable exceptions were
asparagine, which showed significantly lower levels in dough and
bread B but whose levels were unchanged in the sourdough
samples and threonine whose levels were decreased with a longer
fermentation process and which disappeared completely in the
sourdough products. Choline and glycine-betaine, which are
methyl donors, were elevated in both sourdough samples and
those arising from process B compared to the CBP products.
Ethanol, a product of the breadmaking process was present in all
dough and bread samples and was typically higher in samples
receiving a longer fermentation. All doughs had lower levels of
raffinose and maltose than their corresponding bread products,
which is consistent with their use as substrates during proofing.
Changes in faecal microbiota measured by FISH
Eight 16S rRNA-based fluorescence in situ hybridisation
(FISH) probes were used to identify predominant groups, or
species, of human faecal microbiota before and after incubation
with digested bread samples (Table 1). Bacterial numbers of the
samples from IBS donors were compared to the samples obtained
from healthy subjects (Table 3). Numbers of bifidobacteria were
higher in the control group compared to the IBS donors. A
significant increase in bifidobacterial populations occurred (P,
0.005) after 8 hours of fermentation in bread produced with
sourdough (type C) for healthy donors compared to breads
produced with commercial yeast dough and no time fermentation
(type A). No significant changes were also noted in Bacteroides-
Prevotella group populations (detected by Bac303) at all time
points in IBS donors. However, all type of breads stimulated the
growth of bacteria detected by Bac303 at 8 h and over 24 hours
fermentation in healthy donors, but there was no significant
difference compared to the control substrate. No significant
differences were detected for Clostridium histolyticum subgroup
(detected by Chis150) and lactobacilli in IBS and healthy donors.
Significant decreases in d-Proteobacteria and most Gemmatimo-
nadetes (enumerated by probe DELTA495 a-b-c), which are
sulphate-reducing microorganisms, was observed after 24 h
fermentation of type C bread in IBS and healthy donors. This
may be due to the ability of the sourdough bread to enhance the
growth of beneficial bacteria rather than undesirable microorgan-
isms. Cluster IX representatives (detected by Prop853) were
increased by bread type C at 8 h and 24 h in both donor types.
Short chain fatty acid analysis
Short chain fatty acids (SCFAs), which are the principal end
products of gut bacterial metabolism, were measured after 0, 4, 8
and 24 h fermentation with the different test substrates using
HPLC analysis. All substrates gave significant increases in total
SCFA concentration after 8 h of fermentation in both donor types
with fermentation of type C bread leading to significant increases
in concentrations of butyrate after 8 h fermentation in both donor
groups. Acetate was the dominant SCFA produced after 24 h
fermentation with all breads and in both IBS and healthy donors.
Data are shown in Table 4.
Metabolic profiling
Metabolic profiles of fermentation supernatants (Type A, B and
C breads) were acquired at 0, 4, 8 and 24 h post inoculation by
High Resolution 700 MHz NMR spectroscopy. Principal compo-
nent analysis (PCA) revealed a clear trajectory over time, mainly
due to decreasing carbohydrate concentration and increased
production of SCFAs (Figure 1). The cluster of samples isolated by
PC2 displayed a higher polar lipid content (corresponding to
medium chain fatty acids).
Supernatants from the different breads could not be statistically
differentiated from one another but were all distinguished from the
controls due to lower levels of polyethylene glycol (PEG), lipids and
branched chain amino acids in the fermented bread samples
(Figure 2). As expected, all supernatants incubated with bread
samples displayed higher levels of SCFAs compared to controls
(Figure 2).
While the fermentation supernatants (all types of bread) derived
from the IBS and control patients could not be separated at 0 h
post-fermentation, they were clearly separated at 24 h, as
indicated by the PCA displayed in Figure 2A. An Orthogonal
Partial Least Square (O-PLS) analysis also provided significant
discrimination (R2Y= 0.82, R2X=0.10, Q2Y= 0.40; permutation
test based on 1000 random permutations resulted in a p value of
0.003) (Figure 2B). This separation was due to a higher content of
ethanol and taurine in the controls and of proline in the IBS
samples. In order to determine more precisely the extent of
ethanol production after 24 h of fermentation in these 2 groups,
the area under the ethanol resonance of the methyl protons at
1.18 ppm was integrated at 0 h and 24 h (Figure 2C). This shows
a 4 times increase in ethanol production in control-derived
samples while almost no increase was observed in IBS-derived
samples. The large standard error observed in IBS-derived
samples at 24 h was due to the fact that the supernatants from
only one donor contained ethanol.
Gas production kinetics
Gas production during the 36 h of non pH-controlled faecal
batch culture is shown in Figure 3. The rates of gas production for
type A and B breads were almost identical in IBS and healthy
donors, peaking after 6 h, and continuing for up to 36 h (Figure 3
A, B). Type C bread resulted significantly in lower rates combined
with lower total gas production (data not shown) compared to the
control (P,0.05). This indicates that type C was fermented more
slowly to produce a more gradual build-up of gas compared to
other selected breads (Figure 3, B).
Discussion
Irritable bowel syndrome (IBS) is a common functional bowel
disorder, with an estimated worldwide prevalence of 10%–20%
among adults and adolescents. IBS is characterised by pain or
discomfort, disturbed bowel habits and altered stool characteris-
tics. The exact aetiology of IBS is likely to be multifactorial;
moreover, patients diagnosed with the disorder may also be
experiencing bowel symptoms due to different causes. Much
attention has recently been focused on the impact of gastrointes-
tinal microbiota on this disorder [20–26]. Indeed, in recent years,
there has been much greater recognition that bloating results
mainly from abnormal levels of gut fermentation. It is not known
exactly which microbial agents contribute to excessive fermenta-
tion but there is evidence to support a role for both bacteria and
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yeasts [16]. To date, wheat is frequently cited by patients as a
trigger with exclusion of bread and other wheat products often
leading to partial or complete resolution of symptoms [41–43].
Very few studies have investigated the effects of different bread-
making processes on bloating or gastrointestinal symptoms. More
specifically, a change in bread making processes from a traditional
long fermentation process to a short, incomplete fermentation may
have contributed to bread intolerance through its effects on
fermentation in the colon. However, hitherto, there is no
published evidence to support claims that bread made with the
Chorleywood Bread Process (CBP) affects the gastrointestinal
system in a different way compared with the more traditional Bulk
Fermentation Process (BFP) or other commonly used bread-
making processes [10–12].
Our hypothesis is that bread fermented by a traditional long
fermentation technique is less likely to lead to IBS symptoms,
especially gas and bloating, compared to bread made using the
widely used short CBP. In this context, the overall aim of this study
was to compare the fermentation properties of three breads
prepared with different conditions using in vitro batch culture.
Analysis of dough and breads showed clear effects of the
production process on the concentrations of polar metabolites,
including carbohydrates which could affect the pattern of
fermentation in the colon. For example, the sourdough process
resulted in high levels of xylose, arabinose, galactose and mannitol,
none of which are normally detected in flour samples. However,
these differences may well be modulated by digestion and
absorption in the upper part of the GI tract, and may not
therefore represent the composition of the samples entering the
colon.
In vitro studies of digested bread samples were therefore carried
out to determine the impact of the processing system on the
intestinal microbiota and to compare their ability to enhance
faecal bifidobacteria. Bifidobacteria are of particular interest
because this genus is used as a probiotic, does not produce gas,
and has been tested for positive effects on IBS [5]. As expected,
numbers of bifidobacteria were higher in healthy people compared
to IBS donors. The increase in bifidobacteria population was also
significantly higher (P,0.005) after 8 hours of fermentation of
bread produced using a sourdough process (type C) for healthy
people compared to breads produced with commercial yeasted
dough and no time fermentation. In particular, the CBP (type A)
bread showed significant increase in the bifidobacteria populations
Figure 1. Metabolic trajectories of bread fermentated by gut bacteria obtained from both control and IBS patients (n =3). PC1 versus
PC2 scores plot (A) and PC1 loadings (B) derived from the 700 MHz 1H NMR spectra of fermentation supernatants color coded for collection time-
points. Key: Grey: 0 h, Blue: 4 h, Green: 8 h, Orange: 24 h. PC3 versus PC4 scores plot color coded for bread (C) and PC3 loadings (D). Key: Grey:
control, Blue: bread A, Green: bread B, Orange: Bread C.
doi:10.1371/journal.pone.0111225.g001
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(enumerated by probe Bif164) after 24 h. No significant change
was recorded in bifidobacteria numbers in IBS patients.
Short chain fatty acids (SCFAs) were determined after 0, 4, 8
and 24 h fermentation with the different test substrates via HPLC
and NMR techniques. All substrates gave significant increases in
total SCFAs concentrations after 24 h fermentation in both donor
types. Acetate was the dominant SCFA produced in all
fermentations in both IBS and healthy donors. Fermentation of
sourdough (type C) bread led to a significant increase in
concentrations of butyrate. By focusing on faecal short-chain fatty
acids (SCFAs) as the major end product of bacterial metabolism in
the human large intestine, researchers have shown that SCFAs
were increased in diarrhoea-predominant IBS patients and
decreased in constipation-predominant IBS patients. However,
another study reported the conflicting finding that SCFAs are
decreased in diarrhoea-predominant IBS patients, suggesting that
it is necessary to conduct a broader analysis of faecal microbiota,
full profiles of organic acids and simultaneous GI symptoms in IBS
patients [44].
Nevertheless, the suggested link between the SCFAs profile and
GI symptoms can be discussed in the light of the contrasting
biological activities of the SCFAs [45]. Acetate is a known
chemical irritant, and at high concentrations is used to induce
mucosal lesions and abdominal cramps in experimental animals,
while butyrate is considered as protective and able to dose-
dependently reduce abdominal pain in humans in vivo [46]. Tana
and co-workers [46] suggest that altered intestinal microbiota
contributes to the symptoms of IBS through increased levels of
organic acids. Furthermore, IBS patients with high acetic acid or
propionic acid levels presented more severe symptoms, impaired
quality of life and negative emotions. These results are in
accordance with the concept that the gut microbiota influences
the sensory, motor and immune system of the gut and interacts
with higher brain centers [44–50]. Furthermore, metabolomic
analysis of bread fermentation by gut bacteria did not distinguish
between the different types of bread, although they all produced
larger amounts of SCFAs compared to controls, as expected.
Ethanol production was only consistently measured in control
patients while only one IBS volunteer out of three was able to
produce ethanol from bread fermentation. Ethanol is usually
further metabolised to acetate but we could not detect any
significant difference in acetate production between IBS and
control patients and therefore conclude that the absence of ethanol
in IBS patients could not be explained by an increased metabolism
Figure 2. Divergent fermentation of bread samples by IBS and control microbiota. PCA scores plot (A) and O-PLS-DA scores (B) and
associated loadings (C) derived from 700 MHz 1H NMR spectra of fermentation supernatants. Relative ethanol production derived from the integrated
area under the curve of original NMR spectra for the methyl protons at 1.18 ppm. ANOVA: p,2.10216; Multiple comparison test: (a) p,0.0001
different from b and c, (b) p,0.0001 different from a and c. Key: Blue: control; Orange: IBS. *putative assignement.
doi:10.1371/journal.pone.0111225.g002
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to acetate. However, sulphate-reducing bacteria can convert
ethanol to acetate, and this could therefore have occurred
concomitant with the production of higher organic acids.
In vitro gas production was determined in non pH- controlled,
36 h faecal static batch culture tubes. In general, the IBS donors
showed higher rates of gas production and total gas compared to
healthy donors. Similarly, the rates of gas production for type A
and B breads were almost identical in IBS and healthy donors.
Sourdough (type C) bread produced significantly lower cumulative
gas after 15 h fermentation compared to the other types. This was
also observed for the rate of gas production.
To conclude, significant changes were observed in the bacterial
populations with sourdough (type C) bread, including lower
numbers of sulphate-reducing bacteria, i.e., Desulfovibrionales,
compared to types A and B.
Figure 3. Gas production pattern expressed in mL per hour from non-pH controlled batch culture (average results ± standard
deviation of 3 volunteers, n=3) inoculated with healthy faecal microbiota (A); Gas production pattern expressed in mL per hour
from non-pH controlled batch culture (average results ± standard deviation of 3 volunteers, n=3) inoculated with IBS faecal
microbiota (B).
doi:10.1371/journal.pone.0111225.g003
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All types of bread generated some gas after 9 h of fermentation
and the patterns of gas production were similar for type A and B
breads but were both significantly higher than for type C in IBS
donors. In addition, an increase in the concentration of butyrate
was the main impact of all breads on the overall SCFA production.
These findings suggest that sourdough products may be
advantageous for patients suffering from IBS. This study provides
findings supporting the utilization of breads fermented by the
traditional long fermentation and sourdough with a positive effect
on the composition and metabolic profile of the human intestinal
microbiota.
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